Key result
Chronic heart failure costs ~€9,000 annually per patient in Europe, driven primarily by hospitalizations.
Why the study?
The burden of heart failure in North America and Western Europe was not comprehensively depicted using national data on hospitalizations, prevalence, severity, and treatment.
Systematic Review (n=354,550)
Background: We depict the burden of heart failure (HF) in North America (NA) and Western Europe (WE), using a cyclical flow diagram of patients from diagnosis/hospitalization until treatment, stabilization and decompensation/death. Materials & methods: We obtained data on HF hospitalizations, prevalence, severity and treatment from national databases and primary/secondary research. Results: In 2020, we estimate 3.6 and 5.2 million HF hospitalizations, and 7.6 and 8.7 million diagnosed prevalent chronic HF (CHF) cases in NA and WE, respectively. All hospitalized HF and 86-88% of prevalent cases are drug-treated. The most widely prescribed drugs for CHF in NA and WE are β-blockers and loop diuretics, respectively. Conclusion: The high burden of HF in NA and WE calls for greater efforts to prevent ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Goonesekera et al. (2020) conducted a systematic review in Chronic Heart Failure (n=354,550). Chronic Heart Failure was evaluated on Pooled adjusted total mean annual cost per patient with CHF (in 2024 euros) (9001 €/patient/year, 95% CI 6780-11222). The pooled adjusted mean total annual cost of chronic heart failure in Europe was estimated at 9001 € per patient, with hospitalizations accounting for approximately 65% of the total costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: